Extracellular Matrix in Health and Disorders

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Molecular and Translational Medicine".

Deadline for manuscript submissions: 30 November 2024 | Viewed by 1848

Special Issue Editor


E-Mail Website
Guest Editor
Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, Ancona, Italy
Interests: bone; osteoporosis; histology; biomedicine; extracellular matrix

Special Issue Information

Dear Colleagues,

The extracellular matrix (ECM) is a complex structure composed of proteins, glycoproteins, and proteoglycans in different percentages. This variability provides different functional and structural features to many tissues (dermis, bone, tendon, etc.), making the ECM a key point for tissue specialization and physiological processes.

Changes in protein composition and structure, as well as the structural modification of the ECM itself, lead to tissue dysfunctionality, such as photoaging and inadequate matrix repair, and diseases, such as osteoporosis.

Research aimed at clarifying the ECM’s role and qualities is essential for identifying specific targets, designing efficient drugs, and setting clinical strategies able to counter the features of pathological tissues.

This Special Issue aims to collect novel insights into the ECM’s involvement in the normal and altered physiological processes of the skin/dermis, bone, tendon, and other connective tissues.

We are interested in submissions of original research and reviews focusing on the in vivo and ex vivo characterization of the ECM in healthy and pathological tissues, with particular attention paid to structural analyses and advances in imaging, as well as in vitro studies and models, able to increase our knowledge concerning the ECM.

Dr. Caterina Licini
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • ECM
  • connective tissue
  • healthy tissues
  • pathological tissues
  • imaging
  • drug targets
  • markers
  • dermis
  • bone
  • tendon

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

25 pages, 3554 KiB  
Article
Xylosyltransferase-Deficiency in Human Dermal Fibroblasts Induces Compensatory Myofibroblast Differentiation and Long-Term ECM Reduction
by Anika Kleine, Matthias Kühle, Thanh-Diep Ly, Vanessa Schmidt, Isabel Faust-Hinse, Cornelius Knabbe and Bastian Fischer
Biomedicines 2024, 12(3), 572; https://doi.org/10.3390/biomedicines12030572 - 4 Mar 2024
Viewed by 1357
Abstract
Desbuquois dysplasia type 2 (DBQD2) and spondylo-ocular syndrome (SOS) are autosomal recessive disorders affecting the extracellular matrix (ECM) and categorized as glycosaminoglycan (GAG) linkeropathies. Linkeropathies result from mutations within glycosyltransferases involved in the synthesis of the tetrasaccharide linker, a linker between the core [...] Read more.
Desbuquois dysplasia type 2 (DBQD2) and spondylo-ocular syndrome (SOS) are autosomal recessive disorders affecting the extracellular matrix (ECM) and categorized as glycosaminoglycan (GAG) linkeropathies. Linkeropathies result from mutations within glycosyltransferases involved in the synthesis of the tetrasaccharide linker, a linker between the core protein of proteoglycan (PG) and GAG. DBQD2 and SOS are caused by the isolated mutations of the xylosyltransferase (XT) isoforms. In this work, we successfully generated XYLT1- as well as XYLT2-deficient GAG linkeropathy model systems in human dermal fibroblasts using a ribonucleoprotein-based CRISPR/Cas9-system. Furthermore, it was possible to generate a complete XYLT-knockdown. Short- and long-term XT activity deficiency led to the mutual reduction in all linker transferase-encoding genes, suggesting a potential multienzyme complex with mutual regulation. Fibroblasts compensated for ECM misregulation initially by overexpressing ECM through the TGFβ1 signaling pathway, akin to myofibroblast differentiation patterns. The long-term reduction in one XT isoform induced a stress response, reducing ECM components. The isolated XYLT1-knockout exhibited α-smooth muscle actin overexpression, possibly partially compensated by unaltered XT-II activity. XYLT2-knockout leads to the reduction in both XT isoforms and a strong stress response with indications of oxidative stress, induced senescence and apoptotic cells. In conclusion, introducing XYLT-deficiency revealed temporal and isoform-specific regulatory differences. Full article
(This article belongs to the Special Issue Extracellular Matrix in Health and Disorders)
Show Figures

Figure 1

Back to TopTop